Alterity Therapeutics Limited
PRNAF
$0.01
$0.00133.33%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 3.49M | 2.96M | 2.46M | 2.55M | 2.64M |
| Total Revenue | 3.49M | 2.96M | 2.46M | 2.55M | 2.64M |
| Cost of Revenue | 82.60K | 100.80K | 119.30K | 130.20K | 140.60K |
| Gross Profit | 3.41M | 2.86M | 2.34M | 2.42M | 2.50M |
| SG&A Expenses | 3.56M | 3.76M | 3.97M | 3.56M | 3.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 56.70K | 47.40K | 38.30K | 21.10K | 3.40K |
| Total Operating Expenses | 12.99M | 14.46M | 15.99M | 15.78M | 15.51M |
| Operating Income | -9.50M | -11.50M | -13.53M | -13.23M | -12.87M |
| Income Before Tax | -7.85M | -10.42M | -13.02M | -12.80M | -12.53M |
| Income Tax Expenses | 43.10K | 36.50K | 30.40K | 30.40K | 30.40K |
| Earnings from Continuing Operations | -7.89 | -10.46 | -13.05 | -12.83 | -12.56 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.89M | -10.46M | -13.05M | -12.83M | -12.56M |
| EBIT | -9.50M | -11.50M | -13.53M | -13.23M | -12.87M |
| EBITDA | -9.48M | -11.48M | -13.51M | -13.21M | -12.85M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 25.59B | 22.90B | 20.22B | 17.41B | 14.60B |
| Average Diluted Shares Outstanding | 25.59B | 22.90B | 20.22B | 17.41B | 14.60B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |